Interview Dr Mehdi Shahidi Interview Dr Mehdi Shahidi Interview with Dr Mehdi Shahidi, Chief Medical Officer and Head of the Corporate Division Medicine at Boehringer Ingelheim
Our Partners_ViraTherapeutics Our Partners_ViraTherapeutics Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
International Women's Day International Women's Day We celebrate International Women’s Day with this year’s UN Women motto being “Gender Equality Today for a Sustainable Tomorrow”
We get data science We get data science Data scientists and engineers at Boehringer don't have to field the usual ill-conceived questions and comments. Here's their guide on what not to say!
Brand of the Year Frontline pet parasiticides Brand of the Year Frontline pet parasiticides FRONTLINE® Wins Brand of the Year Award for the Third Time in a row
Reimagining digital healthcare worldwide Reimagining digital healthcare worldwide How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes
Boehringer Ingelheim - Whitepaper High throughput cultivation platform microbial strain and process development Boehringer Ingelheim - Whitepaper High throughput cultivation platform microbial strain and process development
Boehringer Ingelheim Climate Seed Report 2022 Climate Contributions Boehringer Ingelheim Climate Seed Report 2022 Climate Contributions
Our partners Bioveta Our partners Bioveta Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Monoclonal Antibody Production | Bioxcellence | Boehringer Ingelheim Monoclonal Antibody Production | Bioxcellence | Boehringer Ingelheim Explore our advanced capabilities in antibody production, and learn about the unique features of monoclonal & polyclonal antibodies.
Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
SIRPα Cancer Immunology Research SIRPα Cancer Immunology Research Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
2024 MORE GREEN infographic - Environmental Stewardship at Boehringer Ingelheim 2024 MORE GREEN infographic - Environmental Stewardship at Boehringer Ingelheim
Animal Health and Animal Welfare at Boehringer Ingelheim Animal Health and Animal Welfare at Boehringer Ingelheim
Boehringer_Ingelheim_consolidated_companies (1).pdf Boehringer_Ingelheim_consolidated_companies (1).pdf
Boehringer_Ingelheim_Consolidated_Companies_2018.pdf Boehringer_Ingelheim_Consolidated_Companies_2018.pdf
Boehringer_Ingelheim_consolidated_companies_2015.pdf Boehringer_Ingelheim_consolidated_companies_2015.pdf
Boehringer_Ingelheim_Consolidated_Companies_2016.pdf Boehringer_Ingelheim_Consolidated_Companies_2016.pdf